Long $NSPH for .40's and beyond
NSPH has moderate negative correlation with larger NASX biotech's. BIB charts implying corrective phase coming. NSPH is a beaten down stock with good risk-reward here and I believe Verigene System (FDA cleared) could be game-changer for Nanosphere.
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.